The success of Pluvicto has created a new challenge in prostate cancer, one the field has not yet fully named or defined.
The post What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape appeared first on MedCity News.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
